Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Unadol Spasma is a fixed-dose combination pharmaceutical product developed and marketed by Uni-Pharma (Syria) for the symptomatic relief of gastrointestinal spasms and associated abdominal pain. It contains paracetamol (acetaminophen), an analgesic and antipyretic, and hyoscine butylbromide (scopolamine butylbromide), a quaternary ammonium antispasmodic agent. Hyoscine butylbromide acts as a competitive antagonist at muscarinic acetylcholine receptors located in the smooth muscle of the gastrointestinal, biliary, and urinary tracts, leading to muscle relaxation and relief from cramping. Paracetamol complements this action by inhibiting prostaglandin synthesis in the central nervous system, thereby elevating the pain threshold. This combination is commonly used for conditions such as irritable bowel syndrome, biliary colic, and renal colic.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Unadol Spasma.